Your data, packaged and sold by @IBM. 'Business analysts said the data dump instantly makes Francisco Partners a significant player in the multibillion-dollar business of buying and selling sensitive information about the care of patients.’ @statnews@caseymross
@IBM@statnews@caseymross How did IBM get all your sensitive health data to sell? They bought other companies that acquired your sensitive health data. And how did they get it? Mostly from 3rd parties who obtained it from health systems, insurers, & others you trust with your data. #privacy#digitalhealth
@IBM@statnews@caseymross And what is being done w/your sensitive data as billion dollar companies buy and sell it? [well, something that makes it valuable to people who want to buy it] And can you reclaim it or get access to it? [no] And is there consequences to orgs that share your sensitive data [no]
@IBM@statnews@caseymross So what will happen next to your data that IBM sold? “It would not surprise me if they’re trying to get to critical mass to then be able to take something public or sell it to one of tother large companies already in this space,” said @thehowie, a prof @YaleMed.
@IBM@statnews@caseymross This buying and selling of your sensitive health data is not Google and FB using data you gave them for ads and more… this is companies using your sensitive health data; data from organizations you trusted to protect your data and not allow it to be passed around as an asset.
@IBM@statnews@caseymross How much did your sensitive health data fetch? 'Under the terms of the sale — which exceeded $1 billion, according to Bloomberg’ @statnews
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Was watching #Dopesick, and I started reflecting on when I first learned IMS (now IQVIA) tracked every prescription by every doc &sold it to pharma so the doctors could be targeted for drug sales… and how inappropriate that seemed to me. And yet I didn’t do anything.
I was on a plane and a drug representative was sitting beside me going through the prescriptions written by doctors he covered - and there was so much detail. Data-drive marketing…& we docs had no idea the companies were tracking us in this way… & IMS was making billions on it.
It felt like an invasion of privacy… & I was puzzled that it could be legal…we were saying at the time that pharma should not be giving gifts…but we didn’t talk about tracking of individual MD's prescribing patterns by the sales teams - and how they acted on that information.
@JAMAInternalMed@ktkadakia@jsross119@AdamLBeckman "JET 7 device was subjected to class I recall following more than 200 adverse event reports, 14 of which involved patient deaths.” We explore the evidence at authorization that the catheter was safe and effective. The findings were disappointing. @YaleMed@YaleCardiology@US_FDA
@JAMAInternalMed@ktkadakia@jsross119@AdamLBeckman@YaleMed@YaleCardiology@US_FDA "Regulatory analysis indicated that each of the Penumbra reperfusion catheters was cleared under the 510(k) pathway (which allows devices to be authorized with limited to no clinical evidence), with limited submission of either new clinical or animal data.” So this is an issue.
Since I drink a lot of tea I really liked this @uk_biobank paper… I am usually skeptical of these types of studies, but this is a good one. “...drinking coffee and tea separately or in combination were associated with lower risk of stroke and dementia.” journals.plos.org/plosmedicine/a…
@uk_biobank I was just a little uncertain why people at the top end of coffee and tea consumption tended to have a higher risk… looked a bit like a j-curve.
@uk_biobank In the table the authors side-stepped it by considering the group with 4 or more cups a day as high coffee and tea consumption and lumped everyone together. For stroke, more dose response for tea than coffee with this approach, and ischemic stroke. Lots of comparisons...
Glad to be part of an in-depth analysis of aortic valve replacement in US elderly, led by remarkable @mori_md & @aakriti_15 w/interdisciplinary team of cardiologists & cardiac surgeons. Findings highlight key trends in the TAVR era. jacc.org/doi/10.1016/j.…@JACCJournals@YaleMed
@mori_md@aakriti_15@JACCJournals@YaleMed@YaleCardiology@ArnarGeirssonMD@ajaykirtane This study took an approach to investigate total aortic valve replacement; often we are looking at the two procedures and comparing them, but missing overall growth of the total procedures and trends in outcomes. More people getting them…and mortality and readmission dropping.
Lots of discussion about science journals…here’s the thing, they do not make it easy on authors. Each journal has their own format, they do not accept each others peer reviewers, they often ask authors to pay for privilege of publishing, and ask authors to donate time to review.
There are so many ways to make this easier… be flexible on format until you decide you want the paper… then you can ask authors to format according to your particular preferences.
Come to agreement about peer reviewers; with each journal starting over with peer reviewers it creates so much more work and delays. There are ways to share among the journals if author so elects.
Great news… @califf001 nomination for @US_FDA seems imminent. And this is a wise choice for someone with the experience, skills and vision to lead at this critical juncture. Sooner we get confirmation, the better. politico.com/news/2021/11/1…
@califf001@US_FDA It is rare to have a Commissioner who has the experience to hit the ground running, and the expertise on the far-reaching responsibilities of the agency, and deeply understands the science. He also knows the potential gamechanging nature of the digital revolution for regulation.
@califf001@US_FDA To move forward we need a Commissioner who can bring people together and fight on behalf of patients for a system that better servess them. I believe that is what @califf001 can do. I have known him a long time, and can judge by actions, not just words.